CODI Q3 2025 Earnings Summary

Overall summary: CODI returned to normal reporting cadence and delivered steady YTD growth ex-Lugano, with strong performance at The Honey Pot and Sterno and support from Altor’s LifePhone acquisition. However, the company posted GAAP losses driven by Lugano-related costs and faces elevated leverage and tariff/geopolitical headwinds. Management is prioritizing deleveraging, evaluating potential asset sales, and positioning for prudent capital returns, while tightening 2025 EBITDA guidance and signaling organic deleveraging in 2026.

Growth

• Consolidated Q3 net sales up 3.5% YoY to $472.6M
• YTD consolidated net sales up 8.6% YoY to $1.4B (+6.1% ex-Lugano)
• YTD subsidiary adjusted EBITDA ex-Lugano up 5.8% YoY to $257M
• Consumer vertical YTD sales up 3.1%, led by strong growth at The Honey Pot and contribution from 5.11
• Industrial vertical YTD sales up mid-to-high single digits, driven primarily by Altor’s 2024 LifePhone acquisition
• The Honey Pot delivering double-digit EBITDA growth and share gains; Sterno delivering double-digit EBITDA growth

Business development

• Altor completed acquisition of LifePhone (driving industrial vertical growth)
• BOA exited lower-value children’s business in China to focus on performance segments
• The Honey Pot expanded from washes/wipes into menstrual category with increased shelf space and strong turns
• 5.11 executed supply chain actions and targeted pricing to navigate tariffs
• Leadership changes at manager: Zach Sautel named COO of Compass Group Management; Pat Maciariello retired; Board member James Bottiglieri retired

Financials

• Q3 GAAP net loss of $87.2M, including Lugano-related expenses and operations
• YTD GAAP net loss of $215M, including $155M loss at Lugano
• Public company costs and management fees YTD: $99.5M, including >$37M one-time Lugano investigation/restatement costs
• Expect Q4 one-time noncash P&L benefit from fee true-up and recognition of a current asset to offset future management fees; aim to fully recoup overpaid fees by 2026
• YTD operating cash flow used: $54M (primarily due to Lugano-related costs); YTD capex: $34M
• Cash and equivalents at Q3 end: $61.1M; < $10M drawn on revolver

Capital & funding

• Credit agreement amended in late 2025; full $100M revolver capacity restored
• Leverage covenant relaxed through 2027; milestone fees begin 6/30/26 if leverage not below 4.5x
• Year-end leverage ratio expected ~5.3x (excluding deconsolidated Lugano)
• Priority on deleveraging organically and via potential value-accretive divestitures; all assets considered saleable at the right value
• Considering efficient return of capital to shareholders when prudent, given perceived valuation discount

Operations & strategy

• Focused on execution post-restatement and returning to normal operating cadence
• Tariff navigation via sourcing/production optimization (e.g., Sterno) and targeted pricing (5.11)
• Investing in subsidiaries to support sustained growth while reducing leverage
• Permanent capital model with engaged ownership and long-term approach
• Insider trading window expected to reopen after filing 2025 Form 10-K and completing audit

Market & outlook

• 2025 characterized by macro uncertainty: geopolitical risks and fluid tariff environment
• 2025 subsidiary adjusted EBITDA guidance ex-Lugano tightened to $335M–$355M
• 2026 expected to see organic deleveraging via growth in subsidiary adjusted EBITDA
• Outlook assumes no material changes in tariffs/geopolitics and no M&A impact

Risks & headwinds

• Tariff volatility and geopolitical uncertainty affecting demand and customer ordering
• Rare earth supply chain disruptions and intermittent export restrictions impacting Arnold
• Elevated leverage (~5.3x ex-Lugano) and associated covenant milestones
• Historical Lugano-related losses and investigation/restatement costs
• Timing constraints on insider share purchases until trading window reopens

Sentiment: mixed